logo

Sierra Oncology, Inc. (SRRA)



Trade SRRA now with
  Date
  Headline
3/3/2020 7:14:55 AM Sierra Oncology Q4 Loss Per Share $7.88 Vs Loss $7.68 Last Year
1/22/2020 7:09:09 AM Sierra Oncology Board Approves Reverse Stock Split Of Shares Of Common Stock At Ratio Of 1-for-40
1/22/2020 7:00:00 AM Sierra Oncology Announces Reverse Stock Split (Press Release)
11/20/2019 7:03:04 AM Sierra Oncology Launches The MOMENTUM Phase 3 Clinical Trial For Patients With Myelofibrosis
11/7/2019 9:04:43 AM Sierra Oncology Agrees To Amend Asset Purchase Agreement With Gilead Sciences For Momelotinib
8/8/2019 7:09:17 AM Sierra Oncology Q2 Net Loss Widens To $14.9 Mln From $12 Mln Last Year
6/5/2019 6:02:54 AM Sierra Oncology Says FDA Granted Fast Track Designation To Momelotinib
6/4/2019 5:06:59 PM Sierra Announces FDA Regulatory Clarity For Momelotinib & Design Of The MOMENTUM Phase 3 Clinical Trial
5/9/2019 10:06:04 AM Wedbush Is Increasing Sierra Oncology, Inc. (SRRA) FY19 Estimate To -0.77 From -0.84
5/9/2019 10:05:52 AM Wedbush Is Increasing Sierra Oncology, Inc. (SRRA) Q4 19 Estimate To -0.21 From -0.22
5/9/2019 10:05:39 AM Wedbush Is Raising Sierra Oncology, Inc. (SRRA) Q3 19 Estimate To -0.20 From -0.22
5/9/2019 10:05:21 AM Wedbush Is Raising Sierra Oncology, Inc. (SRRA) Q2 19 Estimate To -0.19 From -0.21
5/8/2019 7:07:26 AM Sierra Oncology Q1 Net Loss $13.0 Mln Vs Loss Of $11.5 Mln Last Year
2/28/2019 7:20:32 AM Sierra Oncology FY Net Loss $53.3 Mln Vs Loss Of $42.0 Mln Last Year
2/28/2019 7:09:47 AM Sierra Oncology FY Net Loss Widens To $53.3 Mln From $42.0 Mln Last Year
12/3/2018 7:17:05 AM Sierra Oncology Reports Clinical Data For Its Lead Drug Candidate, Momelotinib
11/15/2018 5:01:31 AM Sierra Oncology Reports Preclinical Efficacy For Chk1 Inhibitor SRA737 At EORTC-NCI-AACR Symposium
11/8/2018 7:17:03 AM Sierra Oncology Q3 Net Loss $15.6 Mln Vs. Net Loss $10.0 Mln Last Year
  
 
>